UNSPSC 41141964: Follicle-stimulating hormone test system

In this classification, Follicle-stimulating hormone test system connotes a device used to measure Follicle-stimulating hormone levels. US FDA regulates Follicle-stimulating hormone test system under 21 CFR 862.1300 and under FDA product code NGA.

UNSPSC 41141964 Follicle-stimulating hormone test system is a Commodity code that encompasses diagnostic reagent kits, reference standards, and analytical equipment used in forensic drug testing, public health screening, and laboratory analysis. State and local governments procure under this code to support toxicology and substance-screening operations in crime laboratories, public health agencies, and law enforcement forensic divisions. Recent solicitations show demand for Direct ELISA testing kits for drug metabolites (cannabinoids, opiates, amphetamines, benzodiazepines, and others), certified reference drug standards meeting ISO/IEC 17025 accreditation, DNA screening kits for qualitative PCR analysis, and analytical instrumentation including mass spectrometers and RAMP diagnostic readers for West Nile Virus and dengue detection. Issuing bodies include state law enforcement and criminal justice agencies (Texas Department of Public Safety, Texas Department of Criminal Justice, Florida Department of Law Enforcement), state health and human services departments (Texas Health and Human Services Commission, Illinois Department of Financial and Professional Regulation), county forensic laboratories (Pinellas County, Florida), and state laboratory systems. These are typically formal competitive procurements or sole-source awards where the vendor or product line is unique.

Recent activity concentrates in Texas and Florida. The Texas Department of Public Safety posted an IFB on July 9, 2026 (due July 23, 2026) for immunalysis reagent kits supporting Direct ELISA substance analysis, with 12 line items and one-year term. Pinellas County, Florida, issued an Invitation to Quote on April 23, 2026 for 131 line items of certified reference drug standards (ranging from synthetic cannabinoids to fentanyl analogues) for forensic laboratory validation and evidentiary analysis, funded through the federal Paul Coverdell Forensic Sciences Improvement Act Program with approximately $49,034.00 in equipment and supply allocation. The Texas Health and Human Services Commission released a competitive IFB in February 2026 for QIAxcel and QIAamp DNA screening kits for the DSHS state laboratory, with historical spend of $25,050 to $30,000 in Fiscal Year 2025. The Illinois Department of Financial and Professional Regulation established a joint purchase master contract in May 2026 (sole source to ADAPCO, LLC) for RAMP West Nile Virus and dengue test kits serving multiple jurisdictions nationwide. HUB subcontracting plans and SBE price preferences appear in Texas and Florida solicitations; pricing is typically firm for 12-month initial terms with optional extensions.